



High-Impact Clinical Trials

Live-Stream

Moderators: Kirk N. Campbell, MD, FASN, Wendy L. St. Peter, PharmD, FASN

- 10:30 a.m. [FR-OR61](#) **The TESTING Study: Steroids vs. Placebo in High Risk IgA Nephropathy** - [Vlado Perkovic](#), Jicheng Lv, Muh Geot Wong, Michelle A. Hladunewich, Vivekanand Jha, Helen Monaghan, Hong Zhang
- 10:45 a.m. [FR-OR62](#) **Randomized Controlled Trial Comparing 3- vs. 6-Months Initial Prednisone Therapy in Young (<4-Year-Old) Children with Nephrotic Syndrome** - [Aditi Sinha](#), Pankaj Hari, Arvind Bagga
- 11:00 a.m. [FR-OR63](#) **Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis** - [David R. Jayne](#), Peter A. Merkel, Pirow Bekker, Annette Bruchfeld, Duvuru Geetha, Alexandre Karras, John Niles
- 11:15 a.m. [FR-OR64](#) **ILLUMINATE-C, a Single-Arm, Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 and CKD Stages 3b-5, Including Those on Hemodialysis** - [Mini Michael](#), Jaap Groothoff, Hadas Shasha-Lavsky, John C. Lieske, Yaacov Frishberg, Eva Simkova, Anne-Laure A. Sellier-Leclerc, Arnaud Devresse, Fitsum Guebre Egziabher, Sevcan A. Bakkaloglu, Chebl Mourani, Rola Saqan, Richard F. Singer, Richard G. Willey, Bahru A. Habtemarian, Ishir Bhan, Tracy McGregor, Daniella Magen
- 11:30 a.m. [FR-OR65](#) **Long-Term Results of the Ellipsys Percutaneous Fistula for Hemodialysis** - [Jeffrey E. Hull](#), William C. Jennings, Randy I. Cooper, Rajeev Narayan, Neghae Mawla
- 11:45 a.m. [FR-OR66](#) **ASCEND Program: Efficacy and Safety from ASCEND-D and -ND and Overall MACE Finding** - [Ajay K. Singh](#), Kevin Carroll, Vlado Perkovic, Scott D. Solomon, Vivekanand Jha, Kirsten L. Johansen, Renato D. Lopes, Iain C. Macdougall, Gregorio T. Obrador, Sushrut S. Waikar, Christoph Wanner, David C. Wheeler, Andrzej Wiecek, Allison Blackorby, Borut Cizman, Alexander R. Cobitz, Rich Davies, Tara L. Dimino, Jo F. Dole, Lata Kler, Amy M. Meadowcroft, Lin Taft, Xinyi Zhu, John McMurray
- 12:00 p.m. [FR-OR67](#) **EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and CKD** - [Faiez Zannad](#), Bettina J. Kraus, Cordula Zeller, Stuart Pocock, Milton Packer, Gerasimos Filippatos, João Pedro Ferreira, Stefan D. Anker, Javed Butler
- 12:15 p.m. [FR-OR68](#) **Chlorthalidone for Hypertension in Advanced CKD (CLICK): A Randomized Double-Blind Trial** - [Rajiv Agarwal](#), Arjun D. Sinha, Andrew E. Cramer, Mary Balmes-Fenwick, Jazmyn H. Dickinson, Fangqian Ouyang, Wanzhu Tu
- 12:30 p.m. Adjourn

Note: Full abstracts will be posted online on November 5, 2021.



Late-Breaking Clinical Trials Posters

Posted online on November 4, 2021, 10:00 a.m. PDT

PO2522 Activated Vitamin D for the Prevention of AKI in Critically Ill Patients - [David E. Leaf](#), Sushrut S. Waikar

PO2523 SCD Treatment in COVID-19 ICU Patients with ARDS and AKI Is Safe and May Improve Clinical Outcomes - [Lenar T. Yessayan](#), Javier A. Neyra, Angela Westover, Balazs Szamosfalvi, H. David Humes

PO2524 Effect of Clinical Decision Support with Audit and Feedback for Prevention of AKI in Coronary Angiography and Intervention: Stepped Wedge Cluster Randomized Trial - [Matthew T. James](#), Bryan J. Har, Benjamin D. Tyrrell, Peter D. Faris, Zhi Tan, John Spertus, Stephen B. Wilton, William A. Ghali, Merril L. Knudtson, Neesh I. Pannu, Scott Klarenbach, Michelle M. Graham

PO2525 The Effect of Magnesium Supplementation on Vascular Calcification in CKD: A Randomised Clinical Trial (MAGICAL-CKD) - [Iain O. Bressendorff](#), Ditte Hansen, Morten Schou, Charlotte Kragelund, My Svensson, Bahram Hashemi, Tilde Kristensen, Marie H. Vrist, Rikke Borg, Birgitte G. Tougaard, Kristine Borg, Henrik Øder Hjortkjær, Cathrine H. Kristiansen, Mohammad Nasiri, Haseem Ashraf, Andreas Pasch, Lisbet Brandt

PO2526 REDUX: A Multicenter, Open-Label Study of DM199 (Recombinant Human Tissue Kallikrein-1) in Patients with Stage 2 or 3 CKD - [Harry W. Alcorn](#), Arnold L. Silva, Zachary L. Yablon, Neal A. Patel, Billy T. Hour, Paul W. Crawford

PO2528 Association of Urine Albumin-to-Creatinine Ratio and Its Early Change with Cardiorenal Outcomes in FIDELIO-DKD: A Mediation Analysis - [Rajiv Agarwal](#), Stefan D. Anker, Bertram Pitt, Luis M. Ruilope, Peter Rossing, Meike D. Brinker, Amer Joseph, Robert Lawatscheck, Charlie Scott, Gerasimos Filippatos, George L. Bakris

PO2529 Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: Results from the DARE-19 Randomized Controlled Trial - [Hiddo J. L. Heerspink](#), Remo Furtado, Otavio Berwanger, Gary G. Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Samvel B. Gasparyan, Fengming N. Tang, Sheryl L. Windsor, Joan Buenconsejo, Russell L. Esterline, Jan Oscarsson, Philip D. Ambery, Anna Maria Langkilde, Mikhail Kosiborod

PO2530 Maintaining Operational Excellence During the COVID-19 Pandemic in the FLOW Trial - [Richard E. Pratley](#), George L. Bakris, Willem A. Bax, Heidrun Bosch-Traberg, Kenneth W. Mahaffey, Peter Rossing, Katherine R. Tuttle, Jack Lawson, Camilla Møntegaard, Alfredo Wassermann, Johannes F. Mann

PO2531 Finerenone and Kidney Outcomes in Patients with CKD and T2D: Results from FIDELITY - [George L. Bakris](#), Luis M. Ruilope, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Linda F. Fried, Prabir Roy-Chaudhury, Pantelis Sarafidis, Christiane Ahlers, Amer Joseph, Meike D. Brinker, Robert Lawatscheck, Rajiv Agarwal

PO2532 ACCESS (NCT02513303): A Phase 3 US Multicenter Randomized Controlled Trial Evaluating Efficacy of a Perivascularly Delivered Sirolimus Formulation (Sirogen™) for Improving Hemodialysis AVF Outcomes - [Maria V. DeVita](#), Nelson P. Kopyt, Osman Khawar, Naveen K. Atray, Nirav Gandhi, Kendra S. Hendon, Robert I. Lynn, Sriram Iyer

PO2533 Incremental HD in the US: A Multicenter Pilot Controlled Trial - [Mariana Murea](#), Kamyar Kalantar-Zadeh, Gregory B. Russell

PO2534 A Randomized, Double-Blind, Phase 2 Study to Evaluate the Tolerability, Feasibility, and Efficacy of AKST1210 in Patients on Hemodialysis with ESRD and Cognitive Impairment - [Seema Garg](#), Eva Czirr, Katie Koborsi, Anthony Kalife, Esther Rawner

PO2535 Enhancing Decongestion in Cardiorenal Syndrome by Renal Negative Pressure Diuresis: A First in-Human Experience - [Amir Kazory](#), Alex M. Parker, Vincent G. Bird, Brittany McMichael, David A. Baran



**KIDNEY
WEEK** 20
21

PO2536 Iptacopan, a Novel Oral Complement Factor B (FB) Inhibitor, Significantly Reduces Proteinuria and C3 Deposit Scores in Native and Transplanted Kidneys C3 Glomerulopathy (C3G) Patients - [Edwin K. Wong](#), Carla M. Nester, Teresa Caverio escribano, Alexandre Karras, Moglie Lequintrec-Donnette, Liz Lightstone, Ute Eisenberger, Maria Jose Soler, Andrea Biondani, Frederique Chaperon, Kenneth M. Kulmatycki, Julie M. Milojevic, Prasanna Kumar Nidamarthy, Nicholas Webb, Guido Junge, Giuseppe Remuzzi

PO2537 Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease - [Gopi Rangan](#), Annette Wong, Alexandra Munt, Jennifer Zhang, Sayanthooran Saravanabavan, Margaret Allman-Farinelli, Sunil Badve, Neil Boudville, Bradley J. Erickson, Mangalee R. Fernando, Sheryl L. Foster, Adriana Gregory, Imad A. Haloob, Carmel Hawley, David W. Johnson, Timothy L. Kline, Vincent W. Lee, Maureen A. Lonergan, Elaine Pascoe, Anna M. Rangan, Simon D. Roger, Kamal Sud, Vicente E. Torres, Sundareswari V. Adinarayanan, David Harris

PO2538 PHYOX2: Nedosiran Reduced Urinary Oxalate Excretion in Patients with Primary Hyperoxaluria - [Michelle A. Baum](#), Craig B. Langman, Pierre Cochat, John C. Lieske, Shabbir H. Moochhala, Shuzo Hamamoto, Hiroyuki Satoh, Chebl Mourani, Gema Ariceta, Aniruddha Amrite, Bernd Hoppe

PO2539 Effect of Avacopan, a Selective C5a Receptor Inhibitor, on C3G Histologic Index of Disease Chronicity - [Andrew S. Bomback](#), Leal C. Herlitz, Huibin Yue, Priyanka Punit Kedia, Thomas J. Schall, Pirow Bekker

PO2540 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of Telitaccept in Patients with IgA Nephropathy and Persistent Proteinuria - [Jicheng Lv](#), Lijun Liu, Chuan-Ming Hao, Guisen Li, Ping Fu, Guangqun Xing, Hongguang Zheng, Nan Chen, Wang Caili, Ping Luo, Xie D. Qiong, Li Zuo, Yue Wang, Rongshan Li, Yonghui Mao, Dong Shaoshao, Pengfei Zhang, Hui X. Zheng, Wenxiang Wang, Lin Li, Wenjuan Jiao, Jianmin Fang, Hong Zhang

PO2541 Long-Term Phase 2 Efficacy of the MASP-2 Inhibitor Narsoplímab for Treatment of Severe IgA Nephropathy - [Richard A. Lafayette](#), Kevin Carroll, Jonathan Barratt

PO2542 PODO: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis (FSGS) - Results from First Interim Analysis - [Stephen Berasi](#), J. B. Copley, Donal Gorman, Chay Ngee Lim, Tara Moorehead, Daniel I. Levy, Susan Hwang, Molly Geraghty, Joel M. Henderson, David J. Salant, Weining Lu

PO2543 Serum Aldosterone and Urine Electrolytes Dynamics in Response to DASH Intervention: An Inpatient Mechanistic Study - [Dana Bielopolski](#), Adam Qureshi, Andrea Ronning, Jonathan N. Tobin, Rhonda Kost

PO2544 Early Changes in Estimated Glomerular Filtration Rate Post-Initiation of Empagliflozin in EMPEROR Heart Failure Trials - [Faiez Zannad](#), João Pedro Ferreira, John Gregson, Sibylle J. Hauske, Bettina J. Kraus, Michaela Mattheus, Javed Butler, Gerasimos Filippatos, Christoph Wanner, Stefan D. Anker, Stuart Pocock, Milton Packer

PO2545 AKI and Outcomes Following an Acute Myocardial Infarction - [Finnian R. McCausland](#), Martina M. McGrath, Ebrahim Barkoudah, Brian Claggett, Karola Jering, Eldrin F. Lewis, Mariya Tokmakova, Peter Van Der Meer, Yinong Zhou, Marc A. Pfeffer

PO2546 Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF) - [Matthew M. Lee](#), Sarah Allwood-Spiers, Pauline Hall Barrientos, Kirsty Wetherall, Alex Mcconnachie, Paul Welsh, Giles Roditi, Steven Sourbron, Aleksandra Radjenovic, John McMurray, Pardeep Jhund, Mark C. Petrie, Naveed Sattar, Patrick B. Mark

PO2547 Vitamin K1 Retards Progression of Cardiovascular Calcifications in Hemodialysis Patients: The VitaVasK Trial - [Turgay Saritas](#), Sebastian D. Reinartz, Thilo Krueger, Pieter Evenepoel, Michel Y. Jadoul, Christoph Kopp, Markus Ketteler, Peter Stenvinkel, Ralf Westenfeld, Stephanie Wied, Robert Siepmann, Ralf-dieter Hilgers, Leon J. Schurgers, Jürgen Floege

PO2548 Attenuated COVID-19 Severity in the MDR-101 MLK MERCURY Tolerance Study - [Sam Kant](#), Sanjeev Akkina, William S. Asch, Daniel C. Brennan